Enrolling Studies

Read Our Testimonials

Enrolling Trials

Clinical trials are at the heart of medical advances. Clinical trial participants enroll to possibly receive the latest treatments for their condition, to receive additional care and attention from our professional staff, and to help find better treatments for future patients. In the United States, clinical trials must meet rigorous standards and be registered and approved by regulatory agencies. Participation is free of charge and transportation can be provided for all trial participants. To learn if you are eligible to participate in our enrolling studies, please contact us at:

Call us at 512-279-1251

Email: Ivana Gunderson

About 10-20% of macular degeneration is classified as the wet form. In this form, there is often a rapid onset of distortion and blurring of the vision in one eye due to leakage or bleeding in the macula. If diagnosed early, currently available drugs are quite effective in maintaining or improving vision when injected into the eye. These treatments are not a cure and must be continued indefinitely to maintain vision. When one eye progresses to the wet form of the disease there is an increased risk of about 10% annually for the other to develop the same condition.  Current research is aimed at reducing the number of treatments and improving vision.

  • Boehringer-Ingelheim 1336.0007 – A Phase 1 open label study evaluating BI 836880, a new molecule with a new mechanism of action, in patients with wet AMD.
  • Eyepoint EYP-1901 – A Phase 2 study evaluating a sustained release insert that releases a new drug over time compared to standard of care injections of Eylea in patients with wet AMD.
  • Regenexbio RGX-314-2104 Atmosphere -A Phase 2b/3 study evaluating efficacy of a single administration of RGX-314 Gene Therapy compared to standard of care treatment in patients with wet AMD.
  • 4D Molecular Therapeutics – A Phase 1/2 study evaluating an intravitreal injection of 4D-150 gene therapy in patients with wet AMD.

Diabetic retinopathy is the leading cause of vision loss in working age Americans. It is a common cause of permanent visual impairment in middle age and is a complication of diabetes. The risk of developing diabetic retinopathy is related to length of diabetes and poor diabetic control. It can be asymptomatic and is most commonly found on a routine retinal exam. Diabetes damages the fragile blood vessels in the retina leading to hemorrhages and leakage. Current treatments can reduce the blood vessel damage when the drugs are injected into the eye. Current research is directed at developing longer lasting drugs and treatments that can decrease the severity of diabetic retinopathy to prevent significant complications.

Diabetic patients can have chronic leakage of blood vessels that can lead to diabetic macular edema, or swelling of the retina. This is the leading cause of vision loss from diabetic retinopathy. It causes a progressive blurring of the vision that is not correctable with glasses. This can be successfully treated with current drugs about 60% of the time. Current drugs are injected into the eye on a monthly basis as needed. It is commonly in both eyes, but may not affect both eyes at the same time. Current research is directed at developing more effective and longer lasting treatments.

  • Oxurion THR-149-002 – A phase 2 study evaluating a new treatment approach with drug THR-149 compared to standard of care treatment in patients with diabetic macular edema.
  • Roche BP43445 – A Phase 2 study evaluating a new molecule compared to standard of care treatment in patients with diabetic macular edema.
  • Genentech ML43435 – A Phase 3b/4 open-label study evaluating FDA approved Faricimab in treatment naïve, underrepresented patients with diabetic macular edema.
  • Genentech GR43828 – A Phase 1 open-label study, evaluating a novel drug administered alone or in combination with standard of care Eylea in patients with diabetic macular edema.

Most macular degeneration is classified as the dry form. This label means that there is no associated bleeding or leakage in the macula. The main symptoms are blurred vision or blind spots in the vision. These symptoms are slowly progressive and can ultimately lead to legal blindness. There is currently no FDA approved treatment for this condition. Current research is focused on slowing or stopping the progression of the disease and vision loss.

  • Ionis 696844-CS5 – A Phase 2, placebo-controlled study evaluating multiple doses of IONIS-FB-LRX administered subcutaneously in patients with geography atrophy due to dry age-related macular degeneration (dry AMD).
  • Alexion ALXN2040-GA-201 – A Phase 2, placebo-controlled study of an oral agent, Danicopan, in patients with geographic atrophy secondary to dry age-related macular degeneration (dry AMD).
  • Genentech GR42163 – A Phase 1, open-label, study evaluating a new treatment for geographic atrophy due to dry age-related macular degeneration.
  • Genentech GE43220 – A prospective, observational study of the progression of dry age-related macular degeneration.

Macular telangiectasia type 2 is a rare congenital retinal disease that usually manifests itself in young adults or middle age. It can lead to blurred vision in one or both eyes. There is currently no FDA approved treatment for this condition. We are enrolling patients in a nationwide registry study that will help gather data on this rare condition that may help with future clinical trials and development of treatments. Participating in the registry consists of a one-time in office visit that is of no cost to the patient and benefits include: confirmation of diagnosis by an independent central reader, and to stay informed about future interventional clinical trials.

  • Mactel NHOR– A natural history, observation, and registry study of macular telangiectasia type 2.

Retinal vein occlusions are the third most common retinal disease leading to loss of vision. They are associated with aging of the blood vessels. This can be exacerbated by hypertension and diabetes. Glaucoma is also a risk factor. Current treatments are successful in improving vision about 75% of the time. The treatments include drugs that are injected into the eye and laser surgery. Current research is directed at developing more effective and longer lasting drugs.

  • No enrolling trials at this time.
  • Roche BP40899 Dovetail – A Phase 1 open-label study evaluating a new drug, RO7200220, administered alone or in combination with standard of care treatment in patients with diabetic macular edema or uveitic macular edema.

  • Boehringer-Ingelheim 1451-0001 – A Phase 1/2 study evaluating an in intravitreal injection of a new drug, BI765128 in patient with diabetic retinopathy treated with PRP laser that have diabetic macular ischemia
  • Valo Health OPL-0401-201 – A Phase 2 study to evaluate an oral agent, OPL-0401, in patient with diabetic retinopathy

Closed Trials

Below is a list of trials investigators and staff have participated in. The data has been analyzed by the pharmaceutical companies sponsoring the trials, and those companies have moved the drugs to the next stage of development for the particular medication in question, have submitted for FDA approval, or did not pursue the development of that particular treatment.

9707 Anderson Mill Road,
Suite 100
Austin, TX 78750
Phone:
512-279-1251
Fax:
512-600-2882
©2022. All Rights Reserved.
Designed by Glacial Multimedia
If you are using a screen reader and are having problems using this website, please call 512-279-1251.
Accessibility Disclaimer

Contact Us

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.